Analysts at Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences (NASDAQ:HURA - Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $11.00 price target on the stock. Rodman & Renshaw's target price points to a potential upside of 175.00% from the stock's previous close.
Separately, Maxim Group initiated coverage on shares of TuHURA Biosciences in a report on Tuesday, November 5th. They issued a "buy" rating and a $15.00 target price on the stock.
Get Our Latest Report on HURA
TuHURA Biosciences Trading Down 0.5 %
TuHURA Biosciences stock traded down $0.02 during midday trading on Thursday, hitting $4.00. The company's stock had a trading volume of 159,681 shares, compared to its average volume of 292,876. TuHURA Biosciences has a 1-year low of $2.84 and a 1-year high of $14.60.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
